These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 3413464)

  • 1. [Fasciola hepatica infection. Successful therapy using triclabendazole].
    Markwalder K; Koller M; Goebel N; Wolff K
    Schweiz Med Wochenschr; 1988 Jul; 118(27-28):1048-52. PubMed ID: 3413464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic mass caused by Fasciola hepatica: a tricky differential diagnosis.
    Yilmaz B; Köklü S; Gedikoglu G
    Am J Trop Med Hyg; 2013 Dec; 89(6):1212-3. PubMed ID: 24080633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection.
    Millán JC; Mull R; Freise S; Richter J;
    Am J Trop Med Hyg; 2000; 63(5-6):264-9. PubMed ID: 11421375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Fasciola hepatica infection in horses with triclabendazole.
    Rubilar L; Cabreira A; Giacaman L
    Vet Rec; 1988 Sep; 123(12):320-1. PubMed ID: 3195012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative kinetics of serological and coproantigen ELISA and faecal egg count in cattle experimentally infected with Fasciola hepatica and following treatment with triclabendazole.
    Brockwell YM; Spithill TW; Anderson GR; Grillo V; Sangster NC
    Vet Parasitol; 2013 Sep; 196(3-4):417-26. PubMed ID: 23643623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis.
    Marcos LA; Tagle M; Terashima A; Bussalleu A; Ramirez C; Carrasco C; Valdez L; Huerta-Mercado J; Freedman DO; Vinetz JM; Gotuzzo E
    Am J Trop Med Hyg; 2008 Feb; 78(2):222-7. PubMed ID: 18256419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Failure after Multiple Courses of Triclabendazole among Patients with Fascioliasis in Cusco, Peru: A Case Series.
    Cabada MM; Lopez M; Cruz M; Delgado JR; Hill V; White AC
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004361. PubMed ID: 26808543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of Fasciola hepatica to triclabendazole.
    Overend DJ; Bowen FL
    Aust Vet J; 1995 Jul; 72(7):275-6. PubMed ID: 8534235
    [No Abstract]   [Full Text] [Related]  

  • 9. Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands.
    Winkelhagen AJ; Mank T; de Vries PJ; Soetekouw R
    Emerg Infect Dis; 2012 Jun; 18(6):1028-9. PubMed ID: 22607719
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical presentation and management of Fasciola hepatica infection: single-center experience.
    Kaya M; Beştaş R; Cetin S
    World J Gastroenterol; 2011 Nov; 17(44):4899-904. PubMed ID: 22171131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal egg count reduction test to detect lack of efficacy of triclabendazole.
    Daniel R; van Dijk J; Williams D
    Vet Rec; 2010 Nov; 167(19):759. PubMed ID: 21257517
    [No Abstract]   [Full Text] [Related]  

  • 12. A study of a restricted programme of strategic dosing against Fasciola hepatica with triclabendazole.
    Fawcett AR
    Vet Rec; 1990 Nov; 127(20):492-3. PubMed ID: 2275087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human fascioliasis successfully treated with triclabendazole.
    Laird PP; Boray JC
    Aust N Z J Med; 1992 Feb; 22(1):45-7. PubMed ID: 1580862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical presentation of a very rare infection: parenchymal Fasciola hepatica.
    Sapmaz F; Kalkan IH; Guliter S; Nazlıoğlu A
    Turkiye Parazitol Derg; 2013; 37(4):305-6. PubMed ID: 24412878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human fascioliasis in Egyptian children: successful treatment with triclabendazole.
    el-Karaksy H; Hassanein B; Okasha S; Behairy B; Gadallah I
    J Trop Pediatr; 1999 Jun; 45(3):135-8. PubMed ID: 10401189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fascioliasis: sonographic abnormalities of the biliary tract and evolution after treatment with triclabendazole.
    Richter J; Freise S; Mull R; Millán JC
    Trop Med Int Health; 1999 Nov; 4(11):774-81. PubMed ID: 10588772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole.
    Graham CS; Brodie SB; Weller PF
    Clin Infect Dis; 2001 Jul; 33(1):1-5. PubMed ID: 11389487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of Fasciola hepatica against Triclabendazole in cattle in Cajamarca (Peru): a clinical trial and an in vivo efficacy test in sheep.
    Ortiz P; Scarcella S; Cerna C; Rosales C; Cabrera M; Guzmán M; Lamenza P; Solana H
    Vet Parasitol; 2013 Jul; 195(1-2):118-21. PubMed ID: 23352107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatic fascioliasis. Uncommon cause of prolonged febrile syndrome with hypereosinophilia and hypodense images on computed tomography of the liver].
    Melero M; Rigou RC; Lloveras J; Gennaro O
    Medicina (B Aires); 1991; 51(3):244-8. PubMed ID: 1821909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of radiologically diagnosed pediatric Fasciola hepatica].
    Deveci U; Oztürk T; Ustün C
    Turkiye Parazitol Derg; 2011; 35(2):117-9. PubMed ID: 21776600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.